logo
Flowserve Corporation Reports Second Quarter 2025 Results

Flowserve Corporation Reports Second Quarter 2025 Results

Business Wire29-07-2025
DALLAS--(BUSINESS WIRE)--Flowserve Corporation (NYSE: FLS), a leading provider of flow control products and services for the global infrastructure markets, reported its financial results for the second quarter ended June 30, 2025.
Highlights:
Solid bookings of $1.1 billion, including $621 million of durable aftermarket bookings
Robust gross margin and adjusted 1 gross margin 2 of 34.2% and 34.9%, respectively, both increased 260 basis points versus the prior year period
Operating margin and adjusted operating margin 3 of 12.3% and 14.6%, respectively, expanded 180 and 210 basis points compared to last year
Reported and Adjusted Earnings Per Share (EPS) 4 of 62 and 91 cents, respectively. Reported EPS includes adjusted items of 29 cents, comprised of below-the-line foreign exchange and merger transaction costs among other items
Strong cash from operations of $154 million driven by enhanced earnings generation
Increased full-year 2025 Adjusted EPS guidance from $3.10-$3.30 to $3.25-$3.40, an increase of more than 25% at the midpoint of the range versus last year
Management Commentary:
'Our strong second quarter results reflect the successful ongoing execution of our 3D strategy and the Flowserve Business System. We delivered another quarter of sales and earnings growth while also expanding margins, reflecting the resilience of our business model and progress on our operating initiatives. With the Flowserve Business System firmly established across the organization, we recently went live with our commercial excellence pillar to complement our 80/20 program and drive outsized growth, leveraging the optimized portfolio and delivering the best value to our customers,' said Scott Rowe, Flowserve's President and Chief Executive Officer.
Rowe continued, 'We are encouraged by our momentum through the first half of the year and remain confident in our ability to execute at a high level in any business environment. With our strong performance year-to-date combined with confidence in our outlook, we have increased our full-year adjusted EPS guidance. We are well positioned to deliver on our 2027 long-term targets and create value for our shareholders and stakeholders.'
Merger with Chart Industries, Inc.
In a separate press release issued today, Flowserve announced it has terminated its previously announced merger agreement to combine with Chart Industries, Inc. (NYSE: GTLS) ('Chart'). The termination follows the Flowserve Board of Directors' decision not to submit a revised offer to merge with Chart, after being notified that Chart's Board of Directors had determined that a recent unsolicited acquisition proposal from Baker Hughes (NASDAQ: BKR) constituted a 'superior proposal' under the terms of the merger agreement. In accordance with the terms of the merger agreement, Flowserve will receive a $266 million termination payment.
Key Figures:
(dollars in millions, except per share) 2025 Q2 2024 Q2 Change YTD 2025 YTD 2024 Change
Backlog
$2,853.2
$2,684.4
6.3%
$2,853.2
$2,684.4
6.3%
Bookings
$1,073.9
$1,246.1
(13.8%)
$2,299.4
$2,283.8
0.7%
Original Equipment
$453.3
$632.1
(28.3%)
$990.2
$1,094.1
(9.5%)
Aftermarket
$620.6
$614.0
1.1%
$1,309.2
$1,189.7
10.0%
Sales 5
$1,188.1
$1,156.9
2.7%
$2,332.6
$2,244.4
3.9%
Organic (100) bps 150 bps
Acquisitions 260 bps 290 bps
Foreign Exchange 110 bps (50) bps
Operating Margin
12.3%
10.5%
180 bps
11.9%
10.4%
150 bps
Adjusted Operating Margin
14.6%
12.5%
210 bps
13.8%
11.7%
210 bps
Earnings Per Share
$0.62
$0.55
12.7%
$1.18
$1.11
6.3%
Adjusted Earnings Per Share
$0.91
$0.73
24.7%
$1.63
$1.31
24.4%
Cash From Operations
$154.1
($12.8)
$166.9
$104.2
$49.5
$54.7
Expand
2025 Guidance:
The Company updated its full-year 2025 guidance, including increasing its Adjusted EPS target range.
2025 Adjusted EPS guidance reflects the updated net impact of tariffs and excludes any impact from the Company's annual assessment of actuarial-determined asbestos liabilities, which is typically performed in the third quarter.
Webcast and Conference Call Instructions:
Flowserve will host its conference call to discuss second quarter results on Wednesday, July 30, at 11:00 a.m. Eastern Time. The call can be accessed by shareholders and other interested parties on Flowserve's Investors page.
Footnotes (pages 1-2)
1 See Consolidated Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measure (unaudited) and Segment Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measure (unaudited) tables for a detailed reconciliation of reported results to adjusted measures.
2 Adjusted gross margin is calculated by dividing adjusted gross profit by sales. Adjusted gross profit is derived by excluding the adjusted items.
3 Adjusted operating margin is calculated by dividing adjusted operating income by sales. Adjusted operating income is derived by excluding the adjusted items.
4 Adjusted 2025 EPS excludes potential realignment expenses, below-the-line foreign currency effects, actuarial-determined assessments of certain long-term liabilities and certain other discrete items which may arise during the year and utilizes foreign exchange rates of the prior 30-day period and approximately 132 million fully diluted shares.
5 Organic is defined as the change in Sales, as defined by U.S. GAAP, excluding the impacts of currency translation and acquisitions. The impact of currency translation is calculated by translating current year results on a monthly basis at prior year exchange rates for the same period.
Expand
(Unaudited)
Three Months Ended June 30,
(Amounts in thousands, except per share data)
2025
2024
Sales
$
1,188,092
$
1,156,892
Cost of sales
(781,510
)
(790,796
)
Gross profit
406,582
366,096
Selling, general and administrative expense
(265,908
)
(238,627
)
Loss on sale of business
-
(12,981
)
Net earnings from affiliates
5,916
6,816
Operating income
146,590
121,304
Interest expense
(20,253
)
(16,917
)
Interest income
2,526
1,174
Other expense, net
(25,003
)
(5,263
)
Earnings before income taxes
103,860
100,298
Provision for income taxes
(15,636
)
(23,846
)
Net earnings, including noncontrolling interests
88,224
76,452
Less: Net earnings attributable to noncontrolling interests
(6,470
)
(3,836
)
Net earnings attributable to Flowserve Corporation
$
81,754
$
72,616
Net earnings per share attributable to Flowserve Corporation common shareholders:
Basic
$
0.62
$
0.55
Diluted
0.62
0.55
Weighted average shares – basic
130,846
131,656
Weighted average shares – diluted
131,599
132,415
Expand
Consolidated Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measure (Unaudited)
(Amounts in thousands, except per share data)
Three Months Ended June 30, 2025
Gross Profit
Selling, General & Administrative Expense
Operating Income
Other Income (Expense), Net
Provision For (Benefit From) Income Taxes
Net Earnings (Loss)
Effective Tax Rate
Diluted EPS
Reported
$
406,582
$
265,908
$
146,590
$
(25,003
)
$
15,636
$
81,754
15.1
%
0.62
Reported as a percent of sales
34.2
%
22.4
%
12.3
%
-2.1
%
1.3
%
6.9
%
Realignment charges (a)
5,106
1,787
3,319
-
1,318
2,001
39.7
%
0.02
Acquisition related (b)
752
(3,190
)
3,942
-
927
3,015
23.5
%
0.02
Purchase accounting step-up and intangible asset amortization (c)
2,642
(1,300
)
3,942
-
1,186
2,756
30.1
%
0.02
Discrete items (d)(e)
42
(382
)
424
1,500
453
1,471
23.5
%
0.01
Merger transaction costs (f)
-
(15,515
)
15,515
-
3,649
11,866
23.5
%
0.09
Below-the-line foreign exchange impacts (g)
-
-
-
20,023
2,910
17,113
14.5
%
0.13
Adjusted
$
415,124
$
247,308
$
173,732
$
(3,480
)
$
26,079
$
119,976
17.1
%
0.91
Adjusted as a percent of sales
34.9
%
20.8
%
14.6
%
-0.3
%
2.2
%
10.1
%
Note: Amounts may not calculate due to rounding
(a) Charges represent realignment costs incurred as a result of realignment programs of which $1,500 is non-cash.
(b) Charge represents acquisition and integration related costs associated with the MOGAS acquisition.
(c) Charge represents amortization of step-up in value of acquired inventories and acquisition related intangible assets associated with the MOGAS acquisition.
(d) Charge represents share-based compensation expense associated with a one-time discretionary restricted stock grant, subject to three-year cliff vesting, provided to certain employees in conjunction with the freeze of our US Qualified pension plan.
(e) Charge of $1,500 represents a pension settlement accounting loss incurred in conjunction with the freeze of our US Qualified pension plan.
(f) Charge represents transaction costs incurred associated with the Chart Industries merger.
(g) Below-the-line foreign exchange impacts represent the remeasurement of foreign exchange derivative contracts as well as the remeasurement of assets and liabilities that are denominated in a currency other than a site's respective functional currency.
Three Months Ended June 30, 2024
Gross Profit
Selling, General & Administrative Expense
Loss on Sale of Business
Operating Income
Other Income (Expense), Net
Provision For (Benefit From) Income Taxes
Net Earnings (Loss)
Effective Tax Rate
Diluted EPS
Reported
$
366,096
$
238,627
$
12,981
$
121,304
$
(5,263
)
$
23,846
$
72,616
23.8
%
0.55
Reported as a percent of sales
31.6
%
20.6
%
1.1
%
10.5
%
-0.5
%
2.1
%
6.3
%
Realignment charges (a)
7,521
267
(12,981
)
20,235
-
1,558
18,677
7.7
%
0.14
Discrete items (b)
-
(1,100
)
-
1,100
-
259
841
23.5
%
0.01
Discrete asset write-downs (c)(d)
-
(1,795
)
-
1,795
3,567
1,342
4,020
25.0
%
0.03
Below-the-line foreign exchange impacts (e)
-
-
-
-
207
29
178
13.9
%
0.00
Adjusted
$
373,617
$
235,999
$
-
$
144,434
$
(1,489
)
$
27,034
$
96,332
21.3
%
0.73
Adjusted as a percent of sales
32.3
%
20.4
%
0.0
%
12.5
%
-0.1
%
2.3
%
8.3
%
Note: Amounts may not calculate due to rounding
(a) Charges represent realignment costs incurred as a result of realignment programs of which $19,200 is non-cash.
(b) Charge represents costs associated with merger and acquisition activity.
(c) Charge represents a $1,795 non-cash write-down of a software asset.
(d) Charge represents a $3,567 non-cash write-down of a debt investment.
(e) Below-the-line foreign exchange impacts represent the remeasurement of foreign exchange derivative contracts as well as the remeasurement of assets and liabilities that are denominated in a currency other than a site's respective functional currency.
Expand
SEGMENT INFORMATION
(Unaudited)
FLOWSERVE PUMPS DIVISION
Three Months Ended June 30,
(Amounts in millions, except percentages)
2025
2024
Bookings
$
723.8
$
898.8
Sales
818.9
812.2
Gross profit
299.2
260.2
Gross profit margin
36.5
%
32.0
%
SG&A
142.4
136.1
Segment operating income
162.7
131.0
Segment operating income as a percentage of sales
19.9
%
16.1
%
FLOW CONTROL DIVISION
Three Months Ended June 30,
(Amounts in millions, except percentages)
2025
2024
Bookings
$
354.7
$
349.2
Sales
371.5
347.7
Gross profit
107.7
106.3
Gross profit margin
29.0
%
30.6
%
SG&A
69.9
61.0
Loss on sale of business
-
(13.0
)
Segment operating income
37.8
32.3
Segment operating income as a percentage of sales
10.2
%
9.3
%
Expand
Segment Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measure (Unaudited)
(Amounts in thousands)
Flowserve Pumps Division
Three Months Ended June 30, 2025
Gross Profit
Selling, General & Administrative Expense
Operating Income
Three Months Ended June 30, 2024
Gross Profit
Selling, General & Administrative Expense
Operating Income
Reported
$
299,229
$
142,400
$
162,745
Reported
$
260,215
$
136,053
$
130,978
Reported as a percent of sales
36.5
%
17.4
%
19.9
%
Reported as a percent of sales
32.0
%
16.8
%
16.1
%
Realignment charges (a)
1,888
(1,749
)
3,637
Realignment charges (a)
7,378
720
6,658
Discrete items (b)
35
(99
)
134
Adjusted
$
267,593
$
136,773
$
137,636
Adjusted
$
301,152
$
140,552
$
166,516
Adjusted as a percent of sales
32.9
%
16.8
%
16.9
%
Adjusted as a percent of sales
36.8
%
17.2
%
20.3
%
Flow Control Division
Three Months Ended June 30, 2025
Gross Profit
Selling, General & Administrative Expense
Operating Income
Three Months Ended June 30, 2024
Gross Profit
Selling, General & Administrative Expense
Loss on Sale of Business
Operating Income
Reported as a percent of sales
29.0
%
18.8
%
10.2
%
Reported as a percent of sales
30.6
%
17.6
%
3.7
%
9.3
%
Realignment charges (a)
3,217
3,504
(287
)
Realignment charges (a)
221
53
(12,981
)
13,149
Acquisition related (c)
752
(3,190
)
3,942
Discrete items (b)
-
(1,100
)
-
1,100
Purchase accounting step-up and intangible asset amortization (d)
2,642
(1,300
)
3,942
Adjusted
$
106,492
$
59,987
$
-
$
46,500
Discrete items (b)
5
(99
)
104
Adjusted as a percent of sales
30.6
%
17.3
%
0.0
%
13.4
%
Adjusted
$
114,310
$
68,838
$
45,472
Adjusted as a percent of sales
30.8
%
18.5
%
12.2
%
Note: Amounts may not calculate due to rounding
(a) Charges represent realignment costs incurred as a result of realignment programs of which $1,500 is non-cash.
(a) Charges represent realignment costs incurred as a result of realignment programs of which $19,200 is non-cash.
(b) Charge represents share-based compensation expense associated with a one-time discretionary restricted stock grant, subject to three-year cliff vesting, provided to certain employees in conjunction with the freeze of our US Qualified pension plan.
(b) Charge represents costs associated with merger and acquisition activity.
(c) Charge represents acquisition and integration-related costs associated with the MOGAS acquisition.
(d) Charge represents amortization of step-up in value of acquired inventories and acquisition related intangible assets associated with the MOGAS acquisition.
Expand
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
Six Months Ended June 30,
(Amounts in thousands, except per share data)
2025
2024
Sales
$
2,332,635
$
2,244,371
Cost of sales
(1,556,719
)
(1,539,307
)
Gross profit
775,916
705,064
Selling, general and administrative expense
(509,085
)
(467,045
)
Loss on sale of business
-
(12,981
)
Net earnings from affiliates
11,648
9,344
Operating income
278,479
234,382
Interest expense
(39,428
)
(32,233
)
Interest income
4,271
2,343
Other expense, net
(42,262
)
(6,137
)
Earnings before income taxes
201,060
198,355
Provision for income taxes
(33,379
)
(43,988
)
Net earnings, including noncontrolling interests
167,681
154,367
Less: Net earnings attributable to noncontrolling interests
(12,022
)
(7,531
)
Net earnings attributable to Flowserve Corporation
$
155,659
$
146,836
Net earnings per share attributable to Flowserve Corporation common shareholders:
Basic
$
1.19
$
1.12
Diluted
1.18
1.11
Weighted average shares – basic
131,206
131,583
Weighted average shares – diluted
132,135
132,392
Expand
Consolidated Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measure (Unaudited)
(Amounts in thousands, except per share data)
Six Months Ended June 30, 2025
Gross Profit
Selling, General & Administrative Expense
Operating Income
Other Income (Expense), Net
Provision For (Benefit From) Income Taxes
Net Earnings (Loss)
Effective Tax Rate
Diluted EPS
Reported
$
775,916
$
509,085
$
278,479
$
(42,262
)
$
33,379
$
155,659
16.6
%
1.18
Reported as a percent of sales
33.3
%
21.8
%
11.9
%
-1.8
%
1.4
%
6.7
%
Realignment charges (a)
15,121
3,091
12,030
-
3,189
8,841
26.5
%
0.07
Acquisition related (b)
752
(4,471
)
5,223
-
1,228
3,995
23.5
%
0.03
Purchase accounting step-up and intangible asset amortization (c)
6,117
(2,600
)
8,717
-
2,547
6,170
29.2
%
0.05
Discrete items (d)(e)
75
(765
)
840
3,000
903
2,937
23.5
%
0.02
Merger transaction costs (f)
-
(15,515
)
15,515
-
3,649
11,866
23.5
%
0.09
Below-the-line foreign exchange impacts (g)
-
-
-
31,396
5,355
26,041
17.1
%
0.20
Adjusted
$
797,981
$
488,825
$
320,804
$
(7,866
)
$
50,250
$
215,509
18.1
%
1.63
Adjusted as a percent of sales
34.2
%
21.0
%
13.8
%
-0.3
%
2.2
%
9.2
%
Note: Amounts may not calculate due to rounding
(a) Charges represent realignment costs incurred as a result of realignment programs of which $3,000 is non-cash.
(b) Charge represents acquisition and integration related costs associated with the MOGAS acquisition.
(c) Charge represents amortization of step-up in value of acquired inventories and acquisition related intangible assets associated with the MOGAS acquisition.
(d) Charge represents share-based compensation expense associated with a one-time discretionary restricted stock grant, subject to three-year cliff vesting, provided to certain employees in conjunction with the freeze of our US Qualified pension plan.
(e) Charge of $3,000 represents a pension settlement accounting loss incurred in conjunction with the freeze of our US Qualified pension plan.
(f) Charge represents transaction costs incurred associated with the Chart Industries merger.
(g) Below-the-line foreign exchange impacts represent the remeasurement of foreign exchange derivative contracts as well as the remeasurement of assets and liabilities that are denominated in a currency other than a site's respective functional currency.
Six Months Ended June 30, 2024
Gross Profit
Selling, General & Administrative Expense
Loss on Sale of Business
Operating Income
Other Income (Expense), Net
Provision For (Benefit From) Income Taxes
Net Earnings (Loss)
Effective Tax Rate
Diluted EPS
Reported as a percent of sales
31.4
%
20.8
%
0.6
%
10.4
%
-0.3
%
2.0
%
6.5
%
Realignment charges (a)
13,194
(1,227
)
(12,981
)
27,402
-
2,281
25,121
8.3
%
0.19
Discrete items (b)(c)
-
900
-
(900
)
-
259
(1,159
)
-28.8
%
(0.01
)
Discrete asset write-downs (d)(e)
-
(1,795
)
-
1,795
3,567
1,342
4,020
25.0
%
0.03
Below-the-line foreign exchange impacts (f)
-
-
-
-
(1,116
)
(22
)
(1,094
)
2.0
%
(0.01
)
Adjusted
$
718,258
$
464,923
$
-
$
262,679
$
(3,686
)
$
47,848
$
173,724
20.9
%
1.31
Adjusted as a percent of sales
32.0
%
20.7
%
0.0
%
11.7
%
-0.2
%
2.1
%
7.7
%
Note: Amounts may not calculate due to rounding
(a) Charges represent realignment costs incurred as a result of realignment programs of which $20,000 is non-cash.
(b) Represents a reduction to reserves of $2,000 associated with our ongoing financial exposure in Russia that were adjusted for Non-GAAP measures when established in 2022.
(c) Charge represents $1,100 of costs associated with merger and acquisition activity.
(d) Charge represents a $1,795 non-cash write-down of a software asset.
(e) Charge represents a $3,567 non-cash write-down of a debt investment.
(f) Below-the-line foreign exchange impacts represent the remeasurement of foreign exchange derivative contracts as well as the remeasurement of assets and liabilities that are denominated in a currency other than a site's respective functional currency.
Expand
SEGMENT INFORMATION
(Unaudited)
FLOWSERVE PUMPS DIVISION
Six Months Ended June 30,
(Amounts in millions, except percentages)
2025
2024
Bookings
$
1,576.1
$
1,602.2
Sales
1,602.1
1,581.6
Gross profit
567.7
508.2
Gross profit margin
35.4
%
32.1
%
SG&A
280.1
275.8
Segment operating income
299.3
241.9
Segment operating income as a percentage of sales
18.7
%
15.3
%
FLOW CONTROL DIVISION
Six Months Ended June 30,
(Amounts in millions, except percentages)
2025
2024
Bookings
$
730.4
$
689.9
Sales
735.6
668.2
Gross profit
207.9
199.0
Gross profit margin
28.3
%
29.8
%
SG&A
138.6
119.0
Loss on sale of business
-
(13.0
)
Segment operating income
69.3
67.0
Segment operating income as a percentage of sales
9.4
%
10.0
%
Expand
Segment Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measure (Unaudited)
(Amounts in thousands)
Flowserve Pumps Division
Six Months Ended June 30, 2025
Gross Profit
Selling, General & Administrative Expense
Operating Income
Six Months Ended June 30, 2024
Gross Profit
Selling, General & Administrative Expense
Operating Income
Reported
$
567,691
$
280,080
$
299,259
Reported
$
508,153
$
275,763
$
241,872
Reported as a percent of sales
35.4
%
17.5
%
18.7
%
Reported as a percent of sales
32.1
%
17.4
%
15.3
%
Realignment charges (a)
4,867
(751
)
5,618
Realignment charges (a)
12,422
(321
)
12,743
Discrete items (b)
63
(224
)
287
Discrete item (b)
-
2,000
(2,000
)
Adjusted
$
572,621
$
279,105
$
305,164
Adjusted
$
520,575
$
277,442
$
252,615
Adjusted as a percent of sales
35.7
%
17.4
%
19.0
%
Adjusted as a percent of sales
32.9
%
17.5
%
16.0
%
Flow Control Division
Six Months Ended June 30, 2025
Gross Profit
Selling, General & Administrative Expense
Operating Income
Six Months Ended June 30, 2024
Gross Profit
Selling, General & Administrative Expense
Loss on Sale of Business
Operating Income
Reported
$
207,881
$
138,627
$
69,254
Reported
$
198,966
$
119,026
$
12,981
$
66,959
Reported as a percent of sales
28.3
%
18.8
%
9.4
%
Reported as a percent of sales
29.8
%
17.8
%
1.9
%
10.0
%
Realignment charges (a)
10,319
3,625
6,694
Realignment charges (a)
988
(61
)
(12,981
)
14,030
Acquisition related (c)
752
(4,471
)
5,223
Discrete item (c)
-
(1,100
)
-
1,100
Purchase accounting step-up and intangible asset amortization (d)
6,117
(2,600
)
8,717
Adjusted
$
199,954
$
117,865
$
-
$
82,089
Discrete items (b)
9
(163
)
172
Adjusted as a percent of sales
29.9
%
17.6
%
0.0
%
12.3
%
Adjusted
$
225,078
$
135,018
$
90,060
Adjusted as a percent of sales
30.6
%
18.4
%
12.2
%
Note: Amounts may not calculate due to rounding
Note: Amounts may not calculate due to rounding
(a) Charges represent realignment costs incurred as a result of realignment programs of which $3,000 is non-cash.
(a) Charges represent realignment costs incurred as a result of realignment programs of which $20,000 is non-cash.
(b) Charge represents share-based compensation expense associated with a one-time discretionary restricted stock grant, subject to three-year cliff vesting, provided to certain employees in conjunction with the freeze of our US Qualified pension plan.
(b) Represents a reduction to reserves associated with our ongoing financial exposure in Russia that were adjusted for Non-GAAP measures when established in 2022.
(c) Charge represents acquisition and integration-related costs associated with the MOGAS acquisition.
(c) Charge represents costs associated with merger and acquisition activity.
(d) Charge represents amortization of step-up in value of acquired inventories and acquisition related intangible assets associated with the MOGAS acquisition.
Expand
Second Quarter and Year-to-Date 2025 - Segment Results
(dollars in millions, comparison vs. 2024 second quarter and year-to-date, unaudited)
FPD
FCD
2nd Qtr
Full Year
2nd Qtr
Full Year
Bookings
$
723.8
$
1,576.1
$
354.7
$
730.4
- vs. prior year
-175.1
-19.5
%
-26.2
-1.6
%
5.4
1.6
%
40.5
5.9
%
- on constant currency
-185.0
-20.6
%
-15.8
-1.0
%
3.5
1.0
%
43.5
6.3
%
Sales
$
818.9
$
1,602.1
$
371.5
$
735.6
- vs. prior year
6.8
0.8
%
20.5
1.3
%
23.8
6.8
%
67.3
10.1
%
- on constant currency
-2.3
-0.3
%
30.3
1.9
%
20.4
5.9
%
69.3
10.4
%
Gross Profit
$
299.2
$
567.7
$
107.7
$
207.9
- vs. prior year
15.0
%
11.7
%
1.3
%
4.5
%
Gross Margin (% of sales)
36.5
%
35.4
%
29.0
%
28.3
%
- vs. prior year (in basis points)
450 bps
330 bps
(160) bps
(150) bps
Operating Income
$
162.7
$
299.3
$
37.8
$
69.3
- vs. prior year
31.8
24.2
%
57.4
23.7
%
5.5
17.1
%
2.3
3.4
%
- on constant currency
29.4
22.5
%
58.5
24.2
%
5.6
17.2
%
3.1
4.7
%
Operating Margin (% of sales)
19.9
%
18.7
%
10.2
%
9.4
%
- vs. prior year (in basis points)
380 bps
340 bps
90 bps
(60) bps
Adjusted Operating Income *
$
166.5
$
305.2
$
45.5
$
90.1
- vs. prior year
28.9
21.0
%
52.5
20.8
%
-1.0
-2.2
%
8.0
9.7
%
- on constant currency
26.5
19.3
%
53.7
21.2
%
-1.0
-2.2
%
8.8
10.7
%
Adj. Oper. Margin (% of sales)*
20.3
%
19.0
%
12.2
%
12.2
%
- vs. prior year (in basis points)
340 bps
300 bps
(120) bps
(10) bps
Backlog
$
1,980.7
$
880.9
* Adjusted Operating Income and Adjusted Operating Margin exclude realignment charges and other specific discrete items
Expand
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
June 30,
(Amounts in thousands, except par value)
2025
2024
ASSETS
Current assets:
Cash and cash equivalents
$
629,203
$
675,441
Accounts receivable, net of allowance for expected credit losses of $91,911 and $79,059, respectively
1,049,817
976,739
Contract assets, net of allowance for expected credit losses of $4,577 and $3,404, respectively
339,355
298,906
Inventories
864,532
837,254
Prepaid expenses and other
121,121
116,157
Total current assets
3,004,028
2,904,497
Property, plant and equipment, net of accumulated depreciation of $1,223,841 and $1,142,667, respectively
558,345
539,703
Operating lease right-of-use assets, net
163,171
159,400
Goodwill
1,337,747
1,286,295
Deferred taxes
224,017
221,742
Other intangible assets, net
182,489
188,604
Other assets, net of allowance for expected credit losses of $65,830 and $66,081, respectively
212,728
200,580
Total assets
$
5,682,525
$
5,500,821
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable
$
573,433
$
545,310
Accrued liabilities
495,425
561,486
Contract liabilities
283,181
283,670
Debt due within one year
44,870
44,059
Operating lease liabilities
33,473
33,559
Total current liabilities
1,430,382
1,468,084
Long-term debt due after one year
1,440,676
1,460,132
Operating lease liabilities
148,806
149,838
Retirement obligations and other liabilities
383,659
371,055
Shareholders' equity:
Preferred shares, $1.00 par value
-
-
Shares authorized – 1,000, no shares issued
Common shares, $1.25 par value
220,991
220,991
Shares authorized – 305,000
Shares issued – 176,793 and 176,793, respectively
Capital in excess of par value
489,530
502,045
Retained earnings
4,125,669
4,025,750
Treasury shares, at cost – 46,233 and 45,688 shares, respectively
(2,036,348
)
(2,007,869
)
Deferred compensation obligation
6,413
8,172
Accumulated other comprehensive loss
(583,204
)
(741,424
)
Total Flowserve Corporation shareholders' equity
2,223,051
2,007,665
Noncontrolling interests
55,951
44,047
Total equity
2,279,002
2,051,712
Total liabilities and equity
$
5,682,525
$
5,500,821
Expand
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Six Months Ended June 30,
(Amounts in thousands)
2025
2024
Cash flows – Operating activities:
Net earnings, including noncontrolling interests
$
167,681
$
154,367
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation
38,695
37,883
Amortization of intangible and other assets
9,589
4,391
Loss on sale of business
-
12,981
Stock-based compensation
18,822
17,400
Foreign currency, asset write downs and other non-cash adjustments
(877
)
10,935
Change in assets and liabilities:
Accounts receivable, net
(22,631
)
(168,540
)
Inventories
14,208
3,603
Contract assets, net
(28,930
)
(13,267
)
Prepaid expenses and other, net
13,589
10,945
Accounts payable
(10,414
)
14,376
Contract liabilities
(15,254
)
10,894
Accrued liabilities
(84,466
)
(47,795
)
Retirement obligations and other liabilities
(3,138
)
4,402
Net deferred taxes
7,338
(3,100
)
Net cash flows provided by operating activities
104,212
49,475
Cash flows – Investing activities:
Capital expenditures
(28,340
)
(28,289
)
Proceeds from disposal of assets
867
-
Payments for disposition of business
-
(2,352
)
Other
-
551
Net cash flows (used) by investing activities
(27,473
)
(30,090
)
Cash flows – Financing activities:
Payments on term loan
(18,750
)
(30,000
)
Proceeds under revolving credit facility
50,000
100,000
Payments under revolving credit facility
(50,000
)
(25,000
)
Proceeds under other financing arrangements
3,072
562
Payments under other financing arrangements
(1,231
)
(1,460
)
Repurchases of common shares
(52,797
)
(16,161
)
Payments related to tax withholding for stock-based compensation
(11,337
)
(9,093
)
Payments of dividends
(55,209
)
(55,259
)
Contingent consideration payment related to acquired business
(15,000
)
-
Other
(3,192
)
(272
)
Net cash flows (used) by financing activities
(154,444
)
(36,683
)
Effect of exchange rate changes on cash and cash equivalents
31,467
(13,297
)
Net change in cash and cash equivalents
(46,238
)
(30,595
)
Cash and cash equivalents at beginning of period
675,441
545,678
Cash and cash equivalents at end of period
$
629,203
$
515,083
Expand
About Flowserve:
Flowserve Corporation is one of the world's leading providers of fluid motion and control products and services. Operating in more than 50 countries, the Company produces engineered and industrial pumps, seals and valves as well as a range of related flow management services. More information about Flowserve can be obtained by visiting the Company's website at www.flowserve.com.
Safe Harbor Statement: This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words or phrases such as, "may," "should," "expects," "could," "intends," "plans," "anticipates," "estimates," "believes," "forecasts," "predicts" or other similar expressions are intended to identify forward-looking statements, which include, without limitation, earnings forecasts, statements relating to our business strategy and statements of expectations, beliefs, future plans and strategies and anticipated developments concerning our industry, business, operations and financial performance and condition.
The forward-looking statements included in this news release are based on our current expectations, projections, estimates and assumptions. These statements are only predictions, not guarantees. Such forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict. These risks and uncertainties may cause actual results to differ materially from what is forecast in such forward-looking statements, and include, without limitation, the following: global supply chain disruptions and the current inflationary environment could adversely affect the efficiency of our manufacturing and increase the cost of providing our products to customers; a portion of our bookings may not lead to completed sales, and our ability to convert bookings into revenues at acceptable profit margins; changes in global economic conditions and the potential for unexpected cancellations or delays of customer orders in our reported backlog; our dependence on our customers' ability to make required capital investment and maintenance expenditures; if we are not able to successfully execute and realize the expected financial benefits from any restructuring and realignment initiatives, our business could be adversely affected; the substantial dependence of our sales on the success of the energy, chemical, power generation and general industries; the adverse impact of volatile raw materials prices on our products and operating margins; economic, political and other risks associated with our international operations, including military actions, trade embargoes, epidemics or pandemics and changes to tariffs or trade agreements that could affect customer markets, particularly North African, Latin American, Asian and Middle Eastern markets and global oil and gas producers, and non-compliance with U.S. export/re-export control, foreign corrupt practice laws, economic sanctions and import laws and regulations; the impact of public health emergencies, such as outbreaks of epidemics, pandemics, and contagious diseases, on our business and operations; increased aging and slower collection of receivables, particularly in Latin America and other emerging markets; potential adverse effects resulting from the implementation of new tariffs and related retaliatory actions and changes to or uncertainties related to tariffs and trade agreements; our exposure to fluctuations in foreign currency exchange rates, including in hyperinflationary countries such as Argentina; potential adverse consequences resulting from litigation to which we are a party, such as litigation involving asbestos-containing material claims; expectations regarding acquisitions and the integration of acquired businesses; the potential adverse impact of an impairment in the carrying value of goodwill or other intangible assets; our dependence upon third-party suppliers whose failure to perform timely could adversely affect our business operations; the highly competitive nature of the markets in which we operate; if we are not able to maintain our competitive position by successfully developing and introducing new products and integrate new technologies, including artificial intelligence and machine learning; environmental compliance costs and liabilities; potential work stoppages and other labor matters; access to public and private sources of debt financing; our inability to protect our intellectual property in the United States, as well as in foreign countries; obligations under our defined benefit pension plans; our internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud; the recording of increased deferred tax asset valuation allowances in the future or the impact of tax law changes on such deferred tax assets could affect our operating results; our information technology infrastructure could be subject to service interruptions, data corruption, cyber-based attacks or network security breaches, which could disrupt our business operations and result in the loss of critical and confidential information; ineffective internal controls could impact the accuracy and timely reporting of our business and financial results; and other factors described from time to time in our filings with the Securities and Exchange Commission.
All forward-looking statements included in this news release are based on information available to us on the date hereof, and we assume no obligation to update any forward-looking statement.
The Company reports its financial results in accordance with U.S. generally accepted accounting principles (GAAP). However, management believes that non-GAAP financial measures which exclude certain non-recurring items present additional useful comparisons between current results and results in prior operating periods, providing investors with a clearer view of the underlying trends of the business. Management also uses these non-GAAP financial measures in making financial, operating, planning and compensation decisions and in evaluating the Company's performance. Non-GAAP financial measures, which may be inconsistent with similarly captioned measures presented by other companies, should be viewed in addition to, and not as a substitute for, the Company's reported results prepared in accordance with GAAP.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The Buckle, Inc. Reports July 2025 Net Sales
The Buckle, Inc. Reports July 2025 Net Sales

Yahoo

time8 minutes ago

  • Yahoo

The Buckle, Inc. Reports July 2025 Net Sales

KEARNEY, Neb., August 07, 2025--(BUSINESS WIRE)--The Buckle, Inc. (NYSE: BKE) announced today that comparable store net sales, for stores open at least one year, for the 4-week period ended August 2, 2025 increased 11.0 percent from comparable store net sales for the 4-week period ended August 3, 2024. Net sales for the 4-week fiscal month ended August 2, 2025 increased 12.3 percent to $110.8 million from net sales of $98.7 million for the prior year 4-week fiscal month ended August 3, 2024. Comparable store net sales for the 13-week second quarter ended August 2, 2025 increased 7.3 percent from comparable store net sales for the 13-week period ended August 3, 2024. Net sales for the 13-week fiscal second quarter ended August 2, 2025 increased 8.3 percent to $305.7 million compared to net sales of $282.4 million for the prior year 13-week fiscal second quarter ended August 3, 2024. Comparable store net sales year-to-date for the 26-week period ended August 2, 2025 increased 5.2 percent from comparable store net sales for the 26-week period ended August 3, 2024. Net sales for the 26-week fiscal period ended August 2, 2025 increased 6.1 percent to $577.9 million compared to net sales of $544.9 million for the prior year 26-week fiscal period ended August 3, 2024. The Company will announce second quarter earnings on Friday, August 22, 2025. Management will hold a live audio webcast at 10:00 a.m. EDT on August 22, 2025 to discuss results for the quarter. To register for the live event, visit A replay of the event can be accessed through Buckle's investor relations website within twenty-four hours after the conclusion of the live event ( About Buckle Buckle is a specialty retailer focused on delivering exceptional service and style through unforgettable experiences. Offering a curated mix of high-quality, on-trend apparel, accessories, and footwear, Buckle is for those living the styled life. Known as a denim destination, each store carries a wide selection of fits, styles, and finishes from leading denim brands, including the Company's exclusive brand, BKE. Headquartered in Kearney, Nebraska, Buckle currently operates 440 retail stores in 42 states, which includes the opening of one new store during fiscal July located in Branson, Missouri. The Company operated 440 stores in 42 states as of August 7, 2024. To listen to the Company's recorded monthly sales commentary, please call (308) 238-2500. SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: All forward-looking statements made by the Company involve material risks and uncertainties and are subject to change based on factors which may be beyond the Company's control. Accordingly, the Company's future performance and financial results may differ materially from those expressed or implied in any such forward-looking statements. Such factors include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. News releases and other information on The Buckle, be accessed at View source version on Contacts Thomas B. Heacock, Chief Financial OfficerThe Buckle, Inc. (308) 236-8491 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Yahoo

time8 minutes ago

  • Yahoo

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

– Vidofludimus Calcium Substantially Reduced 24-Week Confirmed Disability Worsening in Phase 2 CALLIPER Trial in Overall Progressive Multiple Sclerosis Study Population and Across Subtypes, Reinforcing the Drug's Neuroprotective Potential and Ability to Slow Disease Progression – – Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026 – – New Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial in Relapsing-Remitting Multiple Sclerosis Showed High Rates of Patients Remaining Free of 12-Week and 24-Week Confirmed Disability Worsening – – Strengthened Balance Sheet with Two Financings Totaling $70.1 Million in Gross Proceeds – NEW YORK, Aug. 7, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the second quarter and six months ended June 30, 2025, and provided a corporate update. "During the second quarter and more recently, we have made substantial clinical progress in advancing our potentially transformative lead asset, vidofludimus calcium (IMU-838), an orally available nuclear receptor-related 1 (Nurr1) activator," stated Daniel Vitt, Ph.D., Chief Executive Officer of Immunic. "Most notable was the on-time completion of enrollment of our twin phase 3 ENSURE trials, bringing us one step closer to delivering a novel treatment option for people living with relapsing multiple sclerosis (RMS). The unique neuroprotective effects observed to date also support the phase 3 ENSURE trials, where confirmed disability worsening will be analyzed. Top-line data from both trials, expected by the end of 2026, will allow for a synchronized readout and a pooled analysis of this clinical endpoint. The growing body of evidence we have amassed continues to strengthen our confidence that, if approved, vidofludimus calcium, with a distinct combination of neuroprotective, anti-inflammatory and anti-viral properties observed, as well as a well-established safety and tolerability profile, has the potential to emerge as a differentiated oral therapy that addresses the complex pathophysiology of multiple sclerosis (MS)." "We also reported strong results from our phase 2 CALLIPER trial in progressive multiple sclerosis (PMS), showing a 23.8% reduction in time to 24-week confirmed disability worsening (24wCDW) in the overall study population compared to placebo. In the high unmet need subgroup of primary progressive MS (PPMS), this effect was 31.3%, exceeding outcomes observed in previous PPMS trials. In another high unmet need subtype, non-active SPMS (naSPMS), the reduction was 19.2%. Moreover, patients without gadolinium-enhancing lesions at baseline, who often do not benefit from existing treatments, saw 24wCDW reductions of 33.7% for the overall PMS population, as well as 34.4% and 29.8% for the PPMS and naSPMS subgroups, respectively. Since time to 24wCDW is a recognized regulatory endpoint for assessing clinical benefit in PMS, we believe these findings strongly support advancing vidofludimus calcium into phase 3 development in progressive forms of MS. With only one approved treatment currently available for PPMS, vidofludimus calcium may be a highly promising option for this underserved $6+ billion market, where reduction of disease progression would allow patients to remain more independent, manage symptoms more easily and achieve better long-term outcomes." Management noted that, among the continued stream of positive data for vidofludimus calcium was the new readout from the long-term open-label extension (OLE) phase of the phase 2 EMPhASIS trial in relapsing-remitting multiple sclerosis (RRMS), which further reinforced the strong efficacy signals previously observed in this trial. Data showed that at week 144, 92.3% of patients remained free of 12-week confirmed disability worsening (12wCDW), and 92.7% were free of 24wCDW. This, and previously announced results across the MS program—including the top-line EMPhASIS and CALLIPER data—further support the potential of vidofludimus calcium to slow disease progression. These findings also continue to highlight its neuroprotective effects, which are believed to be mediated through activation of the Nurr1 target. Based on the strength of the data, a total of five abstracts have been selected for presentation at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in September, including one oral presentation and one late-breaking poster – a major achievement for the company. Dr. Vitt added, "Beyond vidofludimus calcium, compelling clinical and preclinical data for IMU-856, our orally available and systemically acting small molecule modulator that targets sirtuin 6 (SIRT6), indicates the drug's strong promise as a potential novel therapeutic for gastrointestinal disorders. Based on encouraging data available to date, we are preparing for further clinical testing while exploring potential financing, licensing, or partnership opportunities to advance the program. Additionally, IMU-856 has shown potential as an oral treatment option for weight management. More specifically, a post hoc analysis of our phase 1b clinical trial results showed up to a 250% increase in GLP-1 levels versus placebo in fasting celiac disease patients, mimicking natural post-meal responses and suggesting that IMU-856 may activate enteroendocrine pathways physiologically, offering a broader mechanism than current injectable incretin mimetics. If validated in future trials, this once-daily oral small molecule could become a convenient treatment alternative for weight management." Second Quarter 2025 and Subsequent Highlights April 2025: Announced positive data from the phase 2 CALLIPER trial of vidofludimus calcium in patients with PMS. The results demonstrated reduced relative risks of 24wCDW events in the overall study population as well as PMS subtypes compared to placebo. Notably, the drug showed a consistent reduction of disability worsening in subpopulations without inflammatory lesions at baseline and reduced 24wCDW in patients without gadolinium-enhancing lesions at baseline. Vidofludimus calcium substantially reduced the annualized rate of thalamic brain volume loss and the volume of new/enlarging T2 lesions compared to placebo. No new safety signals were identified, confirming the favorable safety and tolerability profile already observed in previous clinical trials. April 2025: Announced a $5.1 million registered direct offering led by Aberdeen Investments. May 2025: Announced an oversubscribed $65 million underwritten public offering. The company may receive up to an aggregate of $130 million of additional proceeds if the Series A Warrants and Series B Warrants are exercised in full for cash. The financing was co-led by BVF Partners and Coastlands Capital, and included participation from Aberdeen Investments, Adage Capital Partners LP, Janus Henderson Investors, and other institutional investors. June 2025: Announced additional data underlining the positive outcome of the phase 2 CALLIPER trial of vidofludimus calcium in patients with PMS. The data for the secondary endpoint of time to 24wCDW, based on the Expanded Disability Status Scale (EDSS), further reinforced the neuroprotective potential of vidofludimus calcium. Similarly, consistent with the top-line data, further analyses of subpopulations – both with and without inflammatory gadolinium-enhanced lesion activity at baseline – continued to demonstrate promising results. June 2025: Announced the on-time completion of enrollment for both phase 3 ENSURE trials of vidofludimus calcium in patients with RMS. In total, 1,121 patients in ENSURE-1 and 1,100 patients in ENSURE-2 have been randomized at more than 100 sites in 15 countries. June 2025: Reported new, long-term OLE data from the phase 2 EMPhASIS trial of vidofludimus calcium in patients with RRMS. At week 144, 92.3% of patients remained free of 12wCDW and 92.7% remaining free of 24wCDW. Vidofludimus calcium continued to demonstrate a favorable safety and tolerability profile with long-term data available up to 5.5 years. Anticipated Clinical Milestones Vidofludimus calcium in MS: Top-line data from the twin phase 3 ENSURE-1 and ENSURE-2 trials is expected by the end of 2026. IMU-856: The company is preparing for further clinical testing of IMU-856, contingent on financing, licensing or partnering. Financial and Operating Results Research and Development (R&D) Expenses were $21.4 million for the three months ended June 30, 2025, as compared to $18.3 million for the three months ended June 30, 2024. The $3.0 million increase reflects (i) a $2.6 million increase in external development costs related to the vidofludimus calcium programs and (ii) a $0.6 million increase in personnel expenses. The increase was offset by a $0.2 million decrease related costs across numerous the six months ended June 30, 2025, R&D expenses were $42.9 million, as compared to $37.1 million for the six months ended June 30, 2024. The $5.8 million increase reflects a $7.3 million increase in external development costs related to the vidofludimus calcium programs. The increase was offset by a $1.5 million decrease in external development costs related to IMU-856 due to the completion of the phase 1b clinical trial in celiac disease patients in 2024. General and Administrative (G&A) Expenses were $5.7 million for the three months ended June 30, 2025, as compared to $4.5 million for the same period ended June 30, 2024. The $1.2 million increase was due to (i) a $0.8 million increase in personnel expenses and (ii) a $0.4 million increase in legal and consultancy expenses. For the six months ended June 30, 2025, G&A expenses were $11.0 million, as compared to $9.6 million for the same period ended June 30, 2024. The $1.4 million increase was due to (i) a $0.7 million increase related to personnel expenses, (ii) a $0.5 million increase in legal and consultancy expenses and (iii) a $0.2 million increase related costs across numerous categories. Interest Income was $0.2 million for the three months ended June 30, 2025, as compared to $1.0 million for the three months ended June 30, 2024. The $0.8 million decrease was due to a lower average cash balance. For the six months ended June 30, 2025, interest income was $0.4 million, as compared to $2.2 million for the same period ended June 30, 2024. The $1.8 million decrease was due to a lower average cash balance. The Change in Fair Value of the Tranche Rights of $4.8 million in the six months ended June 30, 2024, was a non-cash charge related to the change in value of the tranche rights associated with the January 2024 Financing from January 8, 2024 until March 4, 2024. These tranches were initially classified as a liability because the company did not have a sufficient number of authorized shares to issue in tranche 2 and tranche 3 of the offering. But these tranche rights were reclassified to equity on March 4, 2024, when stockholders approved the increase in authorized shares from 130 million to 500 million shares of common stock and therefore the tranche 2 and tranche 3 rights needed to be revalued to fair value upon the reclass to equity. There was no change in fair value of the tranche rights recognized in the six months ended June 30, 2025. Other Income (Expense) was $0.02 million for the three months ended June 30, 2025, as compared to $0.4 million for the same period ended June 30, 2024. The $0.4 million decrease was primarily attributable to activity across numerous categories. For the six months ended June 30, 2025, Other Income (Expense) was $1.2 million, as compared to ($1.7 million) for the same period ending June 30, 2024. The $2.8 million increase was primarily attributable to (i) a $1.7 million expense related to the portion of deal costs from the January 2024 Financing related to the tranche rights that were established at the time of the deal closing in 2024, (ii) a $1.0 million grant income of the German Federal Ministry of Finance recognized in the first quarter 2025 and (iii) a $0.1 million increase across numerous categories. Net Loss for the three months ended June 30, 2025, was approximately $27.0 million, or $0.20 per basic and diluted share, based on 132,175,202 weighted average common shares outstanding, compared to a net loss of approximately $21.4 million, or $0.21 per basic and diluted share, based on 101,272,580 weighted average common shares outstanding for the same period ended June 30, 2024. Net loss for the six months ended June 30, 2025, was approximately $52.3 million, or $0.45 per basic and diluted share, based on 116,844,985 weighted average common shares outstanding, compared to a net loss of approximately $51.0 million or $0.51 per basic and diluted share, based on 99,607,158 weighted average common shares outstanding for the same period ended June 30, 2024. Cash and Cash Equivalents as of June 30, 2025 were $55.3 million. With this cash, the company does not have adequate liquidity to fund its operations for at least twelve months from June 30, 2025, without raising additional capital. About Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: Cautionary Statement Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for Immunic's development programs to safely and effectively target diseases; preclinical and clinical data for Immunic's development programs; the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, and the ability to raise sufficient capital to continue as a going concern, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the company's subsequent filings with the SEC. Copies of these filings are available online at or Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release. Contact Information Immunic, BreuVice President Investor Relations and Communications+49 89 2080 477 US IR ContactRx Communications GroupPaula Schwartz+1 917 633 7790immunic@ US Media ContactKCSA Strategic CommunicationsCaitlin Kasunich+1 212 896 1241ckasunich@ Financials Immunic, Consolidated Statements of Operations(In thousands, except share and per share amounts)(Unaudited) Three Months Ended June 30,Six Months Ended June 30, 2025202420252024 Operating expenses: Research and development$ 21,369$ 18,323$ 42,902$ 37,059 General and administrative5,7144,49111,0069,636 Total operating expenses27,08322,81453,90846,695 Loss from operations(27,083)(22,814)(53,908)(46,695) Other income (expense): Interest income2419984242,185 Change in fair value of the tranche rights———(4,796) Other income (expense), net224361,191(1,658) Total other income (expense)2631,4341,615(4,269) Net loss$ (26,820)$ (21,380)$ (52,293)$ (50,964)Net loss per share, basic and diluted$ (0.20)$ (0.21)$ (0.45)$ (0.51)Weighted-average common shares outstanding, basic and diluted132,175,202101,272,580116,844,98599,607,158 Immunic, Consolidated Balance Sheets(In thousands, except share and per share amounts)(Unaudited)June 30, 2025December 31, 2024(Unaudited) AssetsCurrent assets:Cash and cash equivalents $ 55,310$ 35,668 Other current assets and prepaid expenses 4,5323,664 Total current assets 59,84239,332 Property and equipment, net 612545 Right-of-use assets 975991 Total assets $ 61,429$ 40,868 Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable $ 7,893$ 7,846 Accrued expenses 18,11312,913 Other current liabilities 1,3071,416 Total current liabilities 27,31322,175 Long term liabilitiesOperating lease liabilities 205264 Total long-term liabilities 205264 Total liabilities 27,51822,439 Commitments and contingenciesStockholders' equity:Preferred stock, $0.0001 par value; 20,000,000 shares authorized and no shares issued or outstanding as of June 30, 2025 and December 31, 2024 —— Common stock, $0.0001 par value; 500,000,000 shares authorized as of June 30, 2025 and December 31, 2024, and 98,650,590 and 90,150,869 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 98 Additional paid-in capital 595,069525,611 Accumulated other comprehensive income 2,5254,209 Accumulated deficit (563,692)(511,399) Total stockholders' equity 33,91118,429 Total liabilities and stockholders' equity $ 61,429$ 40,868 View original content to download multimedia: SOURCE Immunic, Inc. Sign in to access your portfolio

Arhaus Reports Second Quarter 2025 Financial Results
Arhaus Reports Second Quarter 2025 Financial Results

Yahoo

time8 minutes ago

  • Yahoo

Arhaus Reports Second Quarter 2025 Financial Results

BOSTON HEIGHTS, Ohio, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Arhaus, Inc. ('Arhaus' or the 'Company') (NASDAQ: ARHS), a growing lifestyle brand and omni-channel retailer of premium artisan-crafted home furnishings, reported second quarter 2025 results for the period ended June 30, 2025. Second Quarter 2025 Highlights Net revenue increased 15.7% to $358 million, compared to the second quarter of 2024 Gross margin increased 19.1% to $148 million, compared to the second quarter of 2024 Selling, general and administrative expenses increased 6.8% to $101 million, compared to the second quarter of 2024 Net and comprehensive income increased 57.7% to $35 million, compared to the second quarter of 2024 Adjusted EBITDA increased 51.2% to $60 million, compared to the second quarter of 2024 Comparable growth(1) of 10.5% Total Showroom Projects(2) of 3 locations, inclusive of 2 relocations and 1 renovation John Reed, Co-Founder and Chief Executive Officer, said: 'We achieved the highest quarterly net revenue in Arhaus' history, exceeding $358 million, reflecting an increase of 15.7%. This record reflects the strength of our brand, the loyalty of our clients, and the exceptional execution of teams across the business. During the quarter, we successfully brought operations of our Dallas Distribution Center in-house which ramped ahead of schedule. This transition enabled us to convert strong first quarter demand into net revenue more efficiently, and at a higher volume, than expected. As a result, Comparable growth(1) was 10.5%. While second-quarter Demand comparable growth(3) was (3.6)%, due to macro headwinds, July rebounded sharply, with Demand comparable growth(3) up an impressive 15.7%, highlighting strong client engagement and the enduring appeal of our products. Year-to-date, including July, Demand comparable growth(3) was up 2.2%. Additionally, I'm proud to announce the launch of our Arhaus Bath Collection. This thoughtful expansion into a deeply personal space in the home reflects our commitment to timeless design, artisan craftsmanship, and functional beauty. With a resilient high-end client base, debt-free balance sheet, and a clear strategic plan, we are navigating the current environment from a position of strength, focused on what we can control: disciplined execution, intentional growth, and continued investment in the systems, products, and talent that will drive our next phase. Thank you to our teams, your creativity, care, and commitment make moments like this possible. Your passion is what brings Arhaus to life.' Business Highlights Arhaus delivered strong second-quarter results, with net revenue exceeding $358 million, up 15.7% and setting a new record for the highest quarterly net revenue in Company history. In the second quarter, Comparable growth(1) was 10.5%, driven by the successful conversion of strong first-quarter demand, while Demand comparable growth(3) was (3.6)%, reflecting macroeconomic volatility and external headwinds. Looking ahead, Demand comparable growth(3) in July was up 15.7%, reflecting strong client engagement and the strength of the Arhaus product assortment. Year-to-date, including July, Demand comparable growth(3) was 2.2%. Showroom Highlights At the end of the second quarter of 2025, Arhaus operated 103 Showrooms across 30 states and all four geographic regions. During the quarter, the Company completed 3 Total Showroom Projects(2), including 2 relocations and 1 renovation. Notable updates include: Wexford, Pennsylvania – A relocated showroom opened in Wexford Plaza, a premium open-air retail destination. The expansive, newly designed space features a dedicated design room and extensive fabric library, serving a key affluent suburb of Pittsburgh and reinforcing Arhaus' luxury positioning. Scottsdale, Arizona – A fully renovated showroom at Kierland Commons. Originally opened in 2015, this renovated space more closely reflects the Arhaus aesthetic, blending international design elements with American craftsmanship to create an eclectic, elevated experience. Year-to-date through the second quarter, Arhaus has completed 8 showroom projects, including 1 new opening, 6 relocations, and 1 renovation. The Company continues to expect the completion of approximately 12 to 15 Total Showroom Projects(2) in 2025, consisting of 4 to 6 new openings and 8 to 9 relocations, renovations, or expansions. Balance Sheet and Liquidity As of June 30, 2025, the Company reported the following: No long-term debt. Cash and cash equivalents totaled $235 million. Net merchandise inventory of $311 million, a 4.7% increase from December 31, 2024 to June 30, 2025. Client deposits of $233 million, a 5.5% increase from December 31, 2024 to June 30, 2025. Net cash provided by operating activities totaled $81 million for the six months ended June 30, 2025. Net cash used in investing activities was approximately $42 million for the six months ended June 30, 2025. Company-funded capital expenditures(4) were approximately $31 million and landlord contributions were approximately $11 million. Outlook The table below reaffirms Arhaus' previously provided expectations for selected full-year 2025 financial and operating metrics. This outlook reflects currently implemented tariff actions as of the date of this release. The Company has also modestly reduced its full-year capital expenditures outlook by $10 million to reflect updated timing on select investments. In addition, Arhaus is introducing third-quarter 2025 guidance for select financial metrics, as detailed below. Full-Year 2025 Q3 2025 Net revenue $1.29 billion to $1.38 billion $320 million to $350 million Net revenue growth 1.5% to 8.6% 0.3% to 9.7% Comparable growth(1) (5)% to 1.5% (4)% to 5% Net income(5) $48 million to $68 million $7 million to $17 million Adjusted EBITDA(6) $123 million to $145 million $23 million to $33 million Company-funded capital expenditures(4) $80 million to $100 million Depreciation & amortization $47 million to $52 million Fully diluted shares ~ 141 million Effective tax rate ~ 26% Showroom openings 4 to 6 new showrooms Total Showroom Projects(2) 12 to 15 showroom projects (1) Comparable growth is a key performance indicator and is defined as the year-over-year percentage change of the dollar value of orders delivered (based on purchase price), net of the dollar value of returns (based on amount credited to client), from our comparable Showrooms and eCommerce, including through our catalogs and other mailings.(2) Total Showroom Projects is defined as the number of showroom projects completed during the period, including new showroom openings, strategic relocations, remodels, and expansions. The Company considers all showroom projects integral to its long-term growth strategy, with each evaluated based on strategic relevance and expected return on investment.(3) Demand comparable growth is a key performance indicator and is defined as the year-over-year percentage change of demand from our comparable Showrooms and eCommerce, including through our catalogs and other mailings.(4) Company-funded capital expenditures is defined as total net cash used in investing activities less landlord contributions.(5) U.S. GAAP net income (loss).(6) We have not reconciled guidance for Adjusted EBITDA to the corresponding GAAP financial measure because we do not provide guidance for the various reconciling items. These items include, but are not limited to, future share-based compensation expense, income taxes, interest income, and transaction costs. We are unable to provide guidance for these reconciling items because we cannot determine their probable significance, as certain items are outside of our control and cannot be reasonably predicted due to the fact that these items could vary significantly from period to period. Accordingly, reconciliations to the corresponding GAAP financial measure is not available without unreasonable effort. Conference Call You are invited to listen to Arhaus' conference call to discuss the second quarter 2025 financial results scheduled for today, August 7, 2025, at 8:30 a.m. Eastern Time. The call will be available over the Internet on our website ( or by dialing (877) 407-3982 within the U.S., or 1 (201) 493-6780, outside the U.S. The conference ID number is 13748992. A recorded replay of the conference call will be available within approximately three hours of the conclusion of the call and can be accessed online at for approximately twelve months. About Arhaus Founded in 1986, Arhaus is a growing lifestyle brand and omni-channel retailer of premium home furnishings. Through a differentiated proprietary model that directly designs and sources products from leading manufacturers and artisans around the world, Arhaus offers an exclusive assortment of heirloom quality products that are sustainably sourced, lovingly made, and built to last. With more than 100 showroom and design studio locations across the United States, a team of interior designers providing complimentary in-home design services, and robust online and eCommerce capabilities, Arhaus is known for innovative design, responsible sourcing, and client-first service. For more information, please visit Investor Contact: Tara Louise AtwoodVice President, Investor Relations(440) 439-7700 invest@ Non-GAAP Financial Measures In addition to the results provided in accordance with U.S. GAAP, this press release and related tables include adjusted EBITDA and adjusted EBITDA as a percentage of net revenue, which present operating results on an adjusted basis. We use non-GAAP measures to help assess the performance of our business, identify trends affecting our business, formulate business plans and make strategic decisions. In addition to our results determined in accordance with U.S. GAAP, we believe that providing these non-GAAP financial measures is useful to our investors as they present an informative supplemental view of our results from period to period by removing the effect of non-recurring items. However, our inclusion of these adjusted measures should not be construed as an indication that our future results will be unaffected by unusual or infrequent items or that the items for which we have made adjustments are unusual or infrequent or will not recur. These non-U.S. GAAP measures are not a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. These measures should only be read together with the corresponding U.S. GAAP measures. Please refer to the reconciliations of adjusted EBITDA to the most directly comparable financial measures prepared in accordance with U.S. GAAP below. Forward-Looking Statements Certain statements contained herein, including statements under the heading 'Outlook' are not based on historical fact and are 'forward-looking statements' within the meaning of applicable securities laws. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, 'may,' 'could,' 'seek,' 'guidance,' 'predict,' 'potential,' 'likely,' 'believe,' 'will,' 'expect,' 'anticipate,' 'estimate,' 'plan,' 'intend,' 'forecast,' or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Past performance is not a guarantee of future results or returns and no representation or warranty is made regarding future performance. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond our control that could cause our actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to manage and maintain the growth rate of our business; our ability to obtain quality merchandise in sufficient quantities; disruption in our receiving and distribution system, including delays in the integration of our distribution centers and the possibility that we may not realize the anticipated benefits of multiple distribution centers; effects of new or proposed tariffs and changes to international trade policies and agreements; the possibility of cyberattacks and our ability to maintain adequate cybersecurity systems and procedures; loss, corruption and misappropriation of data and information relating to clients and employees; changes in and compliance with applicable data privacy rules and regulations; risks as a result of constraints in our supply chain or disruptions due to geopolitical events such as acts of war and/or terrorism or other hostilities; a failure of our vendors to meet our quality standards; declines in general economic conditions that affect consumer confidence and consumer spending that could adversely affect our revenue; our ability to anticipate changes in consumer preferences; risks related to maintaining and increasing Showroom traffic and sales; our ability to compete in our market; our ability to adequately protect our intellectual property; compliance with applicable governmental regulations; effectively managing our eCommerce sales channel and digital marketing efforts; our reliance on third-party transportation carriers and risks associated with freight and transportation costs; and compliance with SEC rules and regulations as a public reporting company. These factors should not be construed as exhaustive. Further information on potential factors that could affect the financial results of the Company and its forward-looking statements is included in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update any forward-looking statement, except as may be required by law. These forward-looking statements speak only as of the date of this release. All forward-looking statements are qualified in their entirety by this cautionary statement. Arhaus, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited, amounts in thousands, except share and per share data) June 30,2025 December 31,2024 Assets Current assets Cash and cash equivalents $ 234,797 $ 197,511 Restricted cash 3,622 3,418 Accounts receivable, net 970 1,252 Merchandise inventory, net 311,117 297,010 Prepaid and other current assets 27,063 31,852 Total current assets 577,569 531,043 Operating right-of-use assets 367,524 322,302 Financing right-of-use assets 34,208 36,105 Property, furniture and equipment, net 303,425 282,520 Deferred tax assets 22,620 21,091 Goodwill 10,961 10,961 Other noncurrent assets 2,069 2,294 Total assets $ 1,318,376 $ 1,206,316 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 70,542 $ 68,621 Accrued taxes 15,602 10,480 Accrued wages 16,413 11,538 Accrued other expenses 43,353 47,668 Client deposits 233,070 220,873 Current portion of operating lease liabilities 55,096 42,247 Current portion of financing lease liabilities 647 1,024 Total current liabilities 434,723 402,451 Operating lease liabilities, long-term 441,945 402,916 Financing lease liabilities, long-term 52,590 53,312 Other long-term liabilities 3,505 3,892 Total liabilities $ 932,763 $ 862,571 Commitments and contingencies Stockholders' equity Class A shares, par value $0.001 per share (600,000,000 shares authorized, 54,400,128 shares issued and 53,859,215 outstanding as of June 30, 2025; 53,788,036 shares issued and 53,514,062 outstanding as of December 31, 2024) 54 53 Class B shares, par value $0.001 per share (100,000,000 shares authorized, 87,115,600 shares issued and outstanding as of June 30, 2025; 87,115,600 shares issued and outstanding as of December 31, 2024) 87 87 Retained earnings 183,047 142,898 Additional paid-in capital 202,425 200,707 Total stockholders' equity 385,613 343,745 Total liabilities and stockholders' equity $ 1,318,376 $ 1,206,316Arhaus, Inc. and Subsidiaries Condensed Consolidated Statements of Comprehensive Income (Unaudited, amounts in thousands, except share and per share data) Six months ended Three months ended June 30, June 30, 2025 2024 2025 2024 Net revenue $ 669,807 $ 604,963 $ 358,435 $ 309,801 Cost of goods sold 405,993 365,537 210,208 185,429 Gross margin 263,814 239,426 148,227 124,372 Selling, general and administrative expenses 211,520 191,684 101,462 94,991 Loss on disposal of assets 108 — — — Income from operations $ 52,186 $ 47,742 $ 46,765 $ 29,381 Interest income, net (1,317 ) (2,038 ) (744 ) (606 ) Other income (236 ) (197 ) (150 ) (75 ) Income before taxes 53,739 49,977 47,659 30,062 Income tax expense 13,791 12,644 12,593 7,828 Net and comprehensive income $ 39,948 $ 37,333 $ 35,066 $ 22,234 Net and comprehensive income per share, basic Weighted-average number of common shares outstanding, basic 140,536,663 139,901,319 140,709,814 139,985,846 Net and comprehensive income per share, basic $ 0.28 $ 0.27 $ 0.25 $ 0.16 Net and comprehensive income per share, diluted Weighted-average number of common shares outstanding, diluted 141,126,879 140,736,096 141,162,310 140,916,161 Net and comprehensive income per share, diluted $ 0.28 $ 0.27 $ 0.25 $ 0.16 Arhaus, Inc. and SubsidiariesCondensed Consolidated Statements of Cash Flows (Unaudited, amounts in thousands) Six months ended June 30, 2025 2024 Cash flows from operating activities Net income $ 39,948 $ 37,333 Adjustments to reconcile net income to net cash provided by operating activities Depreciation and amortization 22,959 17,709 Amortization of operating lease right-of-use asset 20,335 17,942 Amortization of deferred financing fees, interest on finance lease in excess of principal paid and interest on operating leases 14,156 13,008 Equity based compensation 3,390 3,351 Deferred tax assets (1,529 ) 4,870 Amortization of cloud computing arrangements 853 762 Loss on disposal of property, furniture and equipment 108 — Amortization and write-off of lease incentives — (80 ) Changes in operating assets and liabilities Accounts receivable 282 850 Merchandise inventory (14,107 ) (19,265 ) Prepaid and other assets 4,398 (11,545 ) Other noncurrent liabilities (172 ) 332 Accounts payable 1,816 4,571 Accrued expenses 4,746 (11,254 ) Operating lease liabilities (27,952 ) (10,740 ) Client deposits 12,197 36,460 Net cash provided by operating activities 81,428 84,304 Cash flows from investing activities Purchases of property, furniture and equipment (41,622 ) (62,158 ) Net cash used in investing activities (41,622 ) (62,158 ) Cash flows from financing activities Principal payments under finance leases (365 ) (448 ) Repurchase of shares for payment of withholding taxes for equity based compensation (1,675 ) (548 ) Cash dividend payments (276 ) (70,056 ) Net cash used in financing activities (2,316 ) (71,052 ) Net increase (decrease) in cash, cash equivalents and restricted cash 37,490 (48,906 ) Cash, cash equivalents and restricted cash Beginning of period 200,929 226,305 End of period $ 238,419 $ 177,399 Supplemental disclosure of cash flow information Interest paid in cash $ 2,513 $ 2,143 Interest received in cash 4,040 5,155 Income taxes paid in cash 13,030 15,815 Noncash investing activities: Purchase of property, furniture and equipment in current liabilities 7,190 12,672 Arhaus, Inc. and SubsidiariesReconciliation of Net Income to Adjusted EBITDA (Unaudited, amounts in thousands) Six months ended Three months ended June 30, June 30, 2025 2024 2025 2024 Net and comprehensive income $ 39,948 $ 37,333 $ 35,066 $ 22,234 Interest income, net (1,317 ) (2,038 ) (744 ) (606 ) Income tax expense 13,791 12,644 12,593 7,828 Depreciation and amortization 22,959 17,709 11,597 9,106 EBITDA 75,381 65,648 58,512 38,562 Equity based compensation 3,390 3,351 1,795 1,327 Other expenses (1) 108 — — — Adjusted EBITDA $ 78,879 $ 68,999 $ 60,307 $ 39,889 Net revenue $ 669,807 $ 604,963 $ 358,435 $ 309,801 Net and comprehensive income as a % of net revenue 6.0 % 6.2 % 9.8 % 7.2 % Adjusted EBITDA as a % of net revenue 11.8 % 11.4 % 16.8 % 12.9 % ___________________________________________________________(1)Other expenses represent costs and investments not indicative of ongoing business performance, such as loss on disposal of in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store